Clinical Trial Update: A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese [Phase 1]

View source ↗

Summary

Phase 1 clinical trial sponsored by Novo Nordisk evaluating weekly injections of two hormones, GIP and amylin, to assess effects on stomach-related side effects…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Amylin (amylin)
• GIP (glucose-dependent insulinotropic polypeptide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Overweight, Obese | Phase 1 | Status: RECRUITING